

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human PD-1 in direct ELISAs.
<b>Source</b>	Recombinant Monoclonal Rabbit IgG Clone # 2335A
<b>Purification</b>	Protein A or G purified from cell culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line, NS0-derived human PD-1 Met1-Gln167 Accession # Q15116
<b>Conjugate</b>	Alexa Fluor 647 Excitation Wavelength: 650 nm Emission Wavelength: 668 nm
<b>Formulation</b>	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.  *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Flow Cytometry</b>	5 µL/10 <sup>6</sup> cells	Human PBMCs treated with PHA (5 µg/mL) for 5 days

## DATA



## PREPARATION AND STORAGE

<b>Shipping</b>	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Protect from light. Do not freeze.</b> <ul style="list-style-type: none"> <li>12 months from date of receipt, 2 to 8 °C as supplied.</li> </ul>

## BACKGROUND

Programmed Death-1 receptor (PD-1), also known as CD279, is type I transmembrane protein belonging to the CD28 family of immune regulatory receptors (1). Other members of this family include CD28, CTLA-4, ICOS, and BTLA (2-5). Mature human PD-1 consists of a 148 amino acid (aa) extracellular region (ECD) with one immunoglobulin-like V-type domain, a 24 aa transmembrane domain, and a 95 aa cytoplasmic region. The human PD-1 ECD shares 65% aa sequence identity with the mouse PD-1 ECD. The cytoplasmic tail contains two tyrosine residues that form the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important for mediating PD-1 signaling. PD-1 acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (6, 7). PD-1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and also on nonhematopoietic cells such as lung endothelial cells and hepatocytes (8, 9). Ligand of PD-L1 with PD-1 induces co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion (10). Thus, the PD-1: PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance (11). Finally, blockade of the PD-1: PD-L1 interaction by either antibodies or genetic manipulation accelerates tumor eradication and shows potential for improving cancer immunotherapy (12, 13, 14).

## References:

1. Ishida, Y. *et al.* (1992) *EMBO J.* **11**:3887.
2. Sharpe, A.H. and G. J. Freeman (2002) *Nat. Rev. Immunol.* **2**:116.
3. Coyle, A. and J. Gutierrez-Ramos (2001) *Nat. Immunol.* **2**:203.
4. Nishimura, H. and T. Honjo (2001) *Trends Immunol.* **22**:265.
5. Watanabe, N *et al.* (2003) *Nat. Immunol.* **4**:670.
6. Zhang, X. *et al.* (2004) *Immunity* **20**:337.
7. Lázár-Molnár, E. *et al.* (2008) *Proc. Natl. Acad. Sci. USA* **105**:10483.
8. Nishimura, H *et al.* (1996) *Int. Immunol.* **8**:773.
9. Keir, M.E. *et al.* (2008) *Annu. Rev. Immunol.* **26**:677.
10. Butte, M.J. *et al.* (2007) *Immunity* **27**:111.
11. Okazaki, T. *et al.* (2013) *Nat. Immunol.* **14**:1212.
12. Iwai, Y. *et al.* (2002) *Proc. Natl. Acad. Sci. USA* **99**: 12293.
13. Nogrady, B. (2014) *Nature* **513**:S10.
14. Swaika, A. *et al.* (2015) *Mol. Immunol.* **67**: 4

## PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.